{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:04:34Z","timestamp":1760299474305},"reference-count":28,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 14-year-old boy with no significant past medical history presents with headaches and vomiting and is found to have a 2 \u00d7 3-cm left parietal lobe mass. A stereotactic biopsy reveals diffuse large B-cell lymphoma (DLBCL). Cerebrospinal fluid cytology, as well as bone marrow biopsies are negative, and a whole-body positron emission tomography\/computed tomography scan does not demonstrate other areas of disease. The primary medical team asks how you would treat this patient.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.386","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"386-389","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Management of primary central nervous system lymphoma in children"],"prefix":"10.1182","volume":"2016","author":[{"given":"Lisa","family":"Giulino-Roth","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oussama","family":"Abla","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy T.","family":"Batchelor","sequence":"additional","affiliation":[{"name":"Department of Neurology and"},{"name":"Department of Radiation Oncology, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA; and"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"4","key":"2019111707011037300_B1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/bjh.14074","article-title":"Adolescent and young adult non-Hodgkin lymphoma","volume":"173","author":"Hochberg","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111707011037300_B2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.10643","article-title":"Decreasing incidence rates of primary central nervous system lymphoma","volume":"95","author":"Kadan-Lottick","year":"2002","journal-title":"Cancer"},{"issue":"7","key":"2019111707011037300_B3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/pbc.20736","article-title":"A case series of pediatric primary central nervous system lymphoma: favorable outcome without cranial irradiation","volume":"47","author":"Abla","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2019111707011037300_B4","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/foc.2006.21.5.9","article-title":"Primary central nervous system lymphoma in children","volume":"21","author":"Abla","year":"2006","journal-title":"Neurosurg Focus"},{"key":"2019111707011037300_B5","author":"Abla"},{"issue":"5","key":"2019111707011037300_B6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/pbc.25881","article-title":"Rare pediatric non-Hodgkin lymphomas: a report from Children\u2019s Oncology Group Study ANHL 04B1","volume":"63","author":"O\u2019Suoji","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2019111707011037300_B7","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.3324\/haematol.2014.109553","article-title":"Primary central nervous system lymphoma in children and adolescents: low relapse rate after treatment according to Non-Hodgkin-Lymphoma Berlin-Frankfurt-M\u00fcnster protocols for systemic lymphoma","volume":"99","author":"Thorer","year":"2014","journal-title":"Haematologica"},{"issue":"11","key":"2019111707011037300_B8","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3346\/jkms.2012.27.11.1378","article-title":"Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience","volume":"27","author":"Yoon","year":"2012","journal-title":"J Korean Med Sci"},{"issue":"8","key":"2019111707011037300_B9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.2005.04.8819","article-title":"Primary CNS lymphoma","volume":"24","author":"Batchelor","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111707011037300_B10","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"2019111707011037300_B11","author":"Bellinzona"},{"issue":"4","key":"2019111707011037300_B12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/1097-0142(197410)34:4<1293::AID-CNCR2820340441>3.0.CO;2-P","article-title":"Primary malignant lymphomas of the central nervous system","volume":"34","author":"Henry","year":"1974","journal-title":"Cancer"},{"issue":"5","key":"2019111707011037300_B13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3171\/jns.1986.65.5.0600","article-title":"Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature","volume":"65","author":"Murray","year":"1986","journal-title":"J Neurosurg"},{"issue":"2","key":"2019111707011037300_B14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3171\/jns.2000.92.2.0261","article-title":"Primary intracerebral malignant lymphoma: report of 248 cases","volume":"92","author":"Bataille","year":"2000","journal-title":"J Neurosurg"},{"issue":"1","key":"2019111707011037300_B15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1212\/WNL.40.1.80","article-title":"Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy","volume":"40","author":"DeAngelis","year":"1990","journal-title":"Neurology"},{"issue":"12","key":"2019111707011037300_B16","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/neuonc\/nos159","article-title":"Surgery for primary CNS lymphoma? Challenging a paradigm","volume":"14","author":"Weller","year":"2012","journal-title":"Neuro-oncol"},{"issue":"1","key":"2019111707011037300_B17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","article-title":"Non-Hodgkin\u2019s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315","volume":"23","author":"Nelson","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2019111707011037300_B18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2176\/nmc.38.232","article-title":"Primary malignant lymphoma of the brain in childhood","volume":"38","author":"Kai","year":"1998","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"3","key":"2019111707011037300_B19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2000.18.3.519","article-title":"Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma","volume":"18","author":"O\u2019Brien","year":"2000","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111707011037300_B20","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111707011037300_B21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1037\/0022-006X.57.2.251","article-title":"Neuropsychological sequelae of central nervous system prophylaxis in survivors of childhood acute lymphoblastic leukemia","volume":"57","author":"Said","year":"1989","journal-title":"J Consult Clin Psychol"},{"issue":"2","key":"2019111707011037300_B22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1996.14.2.556","article-title":"Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06","volume":"14","author":"Schultz","year":"1996","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111707011037300_B23","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019111707011037300_B24","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"9700","key":"2019111707011037300_B25","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"2019111707011037300_B26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1016077907952","article-title":"Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?","volume":"58","author":"Khan","year":"2002","journal-title":"J Neurooncol"},{"issue":"1","key":"2019111707011037300_B27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11060-011-0649-7","article-title":"Prophylactic intrathecal chemotherapy in primary CNS lymphoma","volume":"106","author":"Sierra Del Rio","year":"2012","journal-title":"J Neurooncol"},{"key":"2019111707011037300_B28","author":"Minard-Colin","year":"2016"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/386\/1252577\/hem088826.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/386\/1252577\/hem088826.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T12:01:20Z","timestamp":1573992080000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/386\/21155\/Management-of-primary-central-nervous-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.386","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}